Ayahuasca Research

Beyer, S. (2008). Women and ayahuasca. Singing to the Plants. https://www.singingtotheplants.com/2008/02/women-and-ayahuasca/

Boyer, E. W., & Shannon, M. (2005). Serotonin Syndrome. The New England Journal of Medicine, 352, 1112-1120.

Brierly, D. I., & Davidson, C. (2012). Developments in harmine pharmacology-
implications for ayahuasca use and drug-dependence treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39, 263-272.

Brown, C. H. (2010). Drug-induced serotonin syndrome. Medscape. Retrieved 02/27/2014 from http://www.medscape.com/viewarticle/733706_1

dos Santos, R. G. (2013a). A Critical Evaluation of Reports Associating Ayahuasca with Life- Threatening Adverse Reactions. Journal of Psychoac.ve Drugs, 45 (2), 179-188.

dos Santos, R. G. (2013b). Safety and side effects of ayahuasca in humans–an overview focusing on developmental toxicology. Journal of Psychoac.ve Drugs, 45 (1), 68-78.

Fischman, L. G. (1983). Dreams, hallucinogenic drug states, and schizophrenia: A psychological and biological comparison. Schizophrenia Bulle.n, 9 (1), 73-94.

Gable, R. S. (2007). Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Society for the Study of Addiction, 102, 24-34.

Guerra, I. (2010, March 23). Peru: Police arrests alleged rapist of German tourist. Living in Peru. Retrieved from http://archive.peruthisweek.com/news-11762-law-order-peru-police-arrests-alleged-rapist-german-tourist

Hearn, K. (2013, March). The dark side of ayahuasca. Men’s Journal. Retrieved from http://www.mensjournal.com/magazine/the-dark-side-of-ayahuasca-20130215

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22 (6), 603-620.
Kahn, M. (1997). Between Therapist and Client: The new relationship (Rev. ed.). New York, NY: W. H. Freeman and Company.

Labate, B. C. (2011). Consumption of ayahuasca by children and pregnant women: medical controversies and religious perspectives. Journal of Psychoac.ve Drugs, 43, (1), 27-35.

McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacology & Therapeutics, 102, 111-129.

Trichter, S. (2011, September 2). Ayahuasca: Beyond the Amazon risks and challenges of a spreading tradition. Retrieved from http://www.ayahuasca.com/psyche/risks-and-challenges-of-a-spreading-tradition/

Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., … Riba, J. (2016). Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Research Bulletin.

McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology & Therapeutics, 102(2), 111–129.

Labate B.C. & Goldstein I. (2009) Ayahuasca – from dangerous drug to national heritage. Intl. J. of Transpersonal Studies, 28(1), 53-64.

McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology & Therapeutics, 102(2), 111–129.

Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006). Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology, 186(1), 93–98.

Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73–83.

Brierley D.I. & Davidson C. (2012). Developments in harmine pharmacology. Prog. Neuro-Pharm. & Biol. Psychiatry, 39, 263-272.

Callaway, J. C., & Grob, C. S. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. Journal of Psychoactive Drugs, 30(4), 367–369.

Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73–83.

Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., … Barbanoj, M. J. (2001). Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology, 154(1), 85–95.

Tupper, K. W. (2009). Ayahuasca healing beyond the Amazon: The globalization of a traditional indigenous entheogenic practice. Global Networks, 9(1), 117–136.

McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology & Therapeutics, 102(2), 111–129.

Thomas et al. (2013). Ayahuasca-assisted therapy for addiction. Curr. Drug Abuse Rev, 6(1), 30-42.

Yakowicz, W. (2015, October 16). Silicon Valley’s Best-Kept Productivity Secret: Psychedelic Drugs.

LaVecchia, O. (2013, November 21). Ayahuasca Can Change Your Life — As Long as You’re Willing to Puke Your Guts Out.

Editor, A. B. A. R., & Post, T. H. (400AD, 26:54). Shaman Explains How Ayahuasca Can Facilitate A Spiritual Awakening.

Cohen, A. (2014, April 21). My Journey With a Life Altering Drug: Ayahuasca.

Hill, D. (2016, July 30). Ayahuasca is changing global environmental consciousness. The Guardian.

https://www.newyorker.com/magazine/2016/09/12/the-ayahuasca-boom-in-the-u-s

Carson, B., Sep. 8, 2016, 26, 047, & 5. (n.d.). This Silicon Valley angel investor loves a drug that gave him hours of seizures.